• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Infect Dis. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients

tetano

Editor, Senior Moderator
Clin Infect Dis. 2020 Mar 4. pii: ciaa203. doi: 10.1093/cid/ciaa203. [Epub ahead of print] [h=1]Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients.[/h]
Shen Z[SUP]1,[/SUP][SUP]2[/SUP], Xiao Y[SUP]3[/SUP], Kang L[SUP]1,[/SUP][SUP]2[/SUP], Ma W[SUP]1,[/SUP][SUP]2[/SUP], Shi L[SUP]1,[/SUP][SUP]2[/SUP], Zhang L[SUP]1[/SUP], Zhou Z[SUP]4[/SUP], Yang J[SUP]1,[/SUP][SUP]2[/SUP], Zhong J[SUP]1,[/SUP][SUP]2[/SUP], Yang D[SUP]5[/SUP], Guo L[SUP]3[/SUP], Zhang G[SUP]6[/SUP], Li H[SUP]7[/SUP], Xu Y[SUP]5[/SUP], Chen M[SUP]8[/SUP], Gao Z[SUP]5[/SUP], Wang J[SUP]3[/SUP], Ren L[SUP]3[/SUP], Li M[SUP]1,[/SUP][SUP]9[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] A novel coronavirus (SARS-CoV-2) has infected more than 75,000 individuals and spread to over 20 countries. It is still unclear how fast the virus evolved and how the virus interacts with other microorganisms in the lung.
[h=4]METHODS:[/h] We have conducted metatranscriptome sequencing for the bronchoalveolar lavage fluid of eight SARS-CoV-2 patients, 25 community-acquired pneumonia (CAP) patients, and 20 healthy controls.
[h=4]RESULTS:[/h] The median number of intra-host variants was 1-4 in SARS-CoV-2 infected patients, which ranged between 0 and 51 in different samples. The distribution of variants on genes was similar to those observed in the population data (110 sequences). However, very few intra-host variants were observed in the population as polymorphism, implying either a bottleneck or purifying selection involved in the transmission of the virus, or a consequence of the limited diversity represented in the current polymorphism data. Although current evidence did not support the transmission of intra-host variants in a person-to-person spread, the risk should not be overlooked. The microbiota in SARS-CoV-2 infected patients was similar to those in CAP, either dominated by the pathogens or with elevated levels of oral and upper respiratory commensal bacteria.
[h=4]CONCLUSION:[/h] SARS-CoV-2 evolves in vivo after infection, which may affect its virulence, infectivity, and transmissibility. Although how the intra-host variant spreads in the population is still elusive, it is necessary to strengthen the surveillance of the viral evolution in the population and associated clinical changes.
? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.


[h=4]KEYWORDS:[/h] COVID-19; SARS-CoV-2; intra-host variant; microbiota; transmission

PMID: 32129843 DOI: 10.1093/cid/ciaa203
 
Back
Top Bottom